Clinical study on the application of a 2‑µm continuous wave laser in transurethral vaporesection of the prostate

Xu,Yong; Sun,Dongchong; Wei,Zhitao; Hong,Baofa; Yang,Yong

doi:10.3892/etm.2013.951

Clinical study on the application of a 2‑µm continuous wave laser in transurethral vaporesection of the prostate

Authors:
- Yong Xu
- Dongchong Sun
- Zhitao Wei
- Baofa Hong
- Yong Yang
View Affiliations

Affiliations: Department of Urology, PLA General Hospital, Beijing 100056, P.R. China
Published online on: February 5, 2013 https://doi.org/10.3892/etm.2013.951
Pages: 1097-1100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the method and clinical effects of transurethral dividing vaporesection of the prostate in the management of benign prostatic hyperplasia (BPH) using the RevoIix 70 W 2‑µm continuous wave (cw) laser. A total of 155 BPH patients were treated transurethrally under epidural or sacral anesthesia using the dividing vaporesection technique. Of these, 80 had a prostate volume of ≤80 ml and 75 had a prostate volume of >80 ml. Pre‑ and post‑operative data were evaluated for prostate‑specific antigens (PSAs), post‑void residual volume (PVR), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS) and quality of life (QoL). Statistical analyses were performed using the SPSS 16.0 software. Treatment effectiveness evaluations were also conducted. In the ≤80 ml prostate volume group, the mean PSA level decreased from 3.8±0.9 to 2.6±1.3 ng/ml. The PVR, mean Qmax, IPSS and QoL score improved significantly (P<0.05) in each group but no statistically significant difference was identified between the two groups. With a shorter surgery duration, safe use and high cutting efficiency and rapid vaporization ability, the 2‑µm laser vaporesection technique shows superiority compared to standard techniques in the treatment of BPH.

View Figures

View References

1	Wu SL, Li NC, Xiao YX, et al: Natural history of benign prostate hyperplasia. Chin Med J (Engl). 119:2085–2089. 2006.PubMed/NCBI
2	Roehrborn CG, Issa MM, Bruskewitz RC, et al: Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology. 51:415–421. 1998. View Article : Google Scholar : PubMed/NCBI
3	de la Rosette JJ, de Wildt MJ, Alivizatos G, Froeling FM and Debruyne FM: Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology. 44:58–63. 1994.PubMed/NCBI
4	Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M and de la Rosette JJ: EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 46:547–554. 2004. View Article : Google Scholar : PubMed/NCBI
5	Gupta N, Sivaramakrishna, Kumar R, Dogra PN and Seth A: Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int. 97:85–89. 2006.
6	Kuntz RM: Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol. 49:961–969. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fraundorfer MR and Gilling PJ: Holmium: YAG laser enucleation of the prostate combined with mechanical morcellation: preliminary results. Eur Urol. 33:69–72. 1998. View Article : Google Scholar : PubMed/NCBI
8	Fried NM and Murray KE: High-power thulium fiber ablation of urinary tissues at 1.94 microm. J Endourol. 19:25–31. 2005. View Article : Google Scholar : PubMed/NCBI
9	Araki M, Lam PN and Wong C: High-power potassium-titanyl-phosphate laser photoselective vaporization prostatectomy for symptomatic benign prostatic hyperplasia. J Endourol. 22:1311–1314. 2008. View Article : Google Scholar
10	Fu WJ, Hong BF, Yang Y, et al: Two micron continuous wave laser vaporesection for the treatment of benign prostatic hyper-plasia. Asian J Androl. 10:341–342. 2008. View Article : Google Scholar : PubMed/NCBI
11	Fu WJ, Hong BF, Yang Y, et al: Vaporesection for managing benign prostatic hyperplasia using a 2-microm continuous-wave laser: a prospective trial with 1-year follow-up. BJU Int. 103:352–356. 2009.PubMed/NCBI
12	Luo GH, Xia SJ and Sun ZL: In vitro comparison of the vapore-section of human benign prostatic hyperplasia using 70- and 120-W 2-μm lasers. Asian J Androl. 13:636–639. 2011. View Article : Google Scholar : PubMed/NCBI
13	Fu WJ, Zhang X, Yang Y, et al: Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective nonrandomized trial with 1-year follow-up. Urology. 75:194–199. 2010.PubMed/NCBI
14	Pal RP and Khan MA: Intermediate-term efficacy of Tm: YAG laser prostate vaporesection for bladder outlet obstruction: initial experience from a UK teaching hospital. Urol Int. 88:39–42. 2012. View Article : Google Scholar : PubMed/NCBI
15	Malek RS, Kuntzman RS and Barrett DM: Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol. 174:1344–1348. 2005. View Article : Google Scholar : PubMed/NCBI
16	Elzayat EA and Elhilali MM: Laser treatment of symptomatic benign prostatic hyperplasia. World J Urol. 24:410–417. 2006. View Article : Google Scholar : PubMed/NCBI
17	Vavassori I, Hurle R, Vismara A, Manzetti A and Valenti S: Holmium laser enucleation of the prostate combined with mechanical morcellation: two years of experience with 196 patients. J Endourol. 18:109–112. 2004.PubMed/NCBI
18	Xia SJ: Two-micron (thulium) laser resection of the prostate-tangerine technique: a new method for BPH treatment. Asian J Androl. 11:277–281. 2009. View Article : Google Scholar : PubMed/NCBI
19	Bach T, Herrmann TR, Ganzer R, Burchardt M and Gross AJ: RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol. 25:257–262. 2007.PubMed/NCBI